Literature DB >> 25707372

[Antihypertensive drug therapy : Where do we stand?].

M Middeke1.   

Abstract

Antihypertensive drug therapy is one of the most successful medical measures ever, at all levels. The treatment situation in Germany has clearly improved in recent years. Nowadays, a wide range of very effective and well-tolerated hypertensive substances is available. Combination therapy has a long and successful tradition in hypertensive treatment, especially with suitable fixed combinations. Furthermore, the administration of fixed combinations is very beneficial to therapy adherence because it is essentially dependent on the number of drugs to be taken. The value of beta blockers and the double blockade of the renin-angiotensin-aldosterone system are under discussion and the interpretation of corresponding studies must be conducted very carefully. The hypertensive effect of a substance cannot be comprehensively assessed without taking the time of day, the time point of measurement and the time point of intake into consideration. This is particularly important with respect to the effect over 24 h. Optimal antihypertensive therapy must also take into consideration the individual blood pressure rhythm with respect to the dose and dosing intervals. The importance of the central (aortic) blood pressure as target blood pressure will increase.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25707372     DOI: 10.1007/s00108-014-3570-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  28 in total

1.  Effect of forced titration of nebivolol on response rate in obese hypertensive patients.

Authors:  Tobias Pischon; Arya M Sharma; Ulrich Mansmann; Rahul Agrawal
Journal:  Am J Hypertens       Date:  2003-01       Impact factor: 2.689

2.  Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Authors:  Luis Miguel Ruilope; Andrej Dukat; Michael Böhm; Yves Lacourcière; Jianjian Gong; Martin P Lefkowitz
Journal:  Lancet       Date:  2010-03-16       Impact factor: 79.321

3.  Low-dose spironolactone in the management of resistant hypertension: a surveillance study.

Authors:  Deirdre A Lane; Sarah Shah; D Gareth Beevers
Journal:  J Hypertens       Date:  2007-04       Impact factor: 4.844

4.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

5.  [Pulse wave analysis].

Authors:  M Middeke
Journal:  Dtsch Med Wochenschr       Date:  2010-02-23       Impact factor: 0.628

6.  Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men.

Authors:  K Brixius; M Middeke; A Lichtenthal; E Jahn; R H G Schwinger
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-04       Impact factor: 2.557

7.  Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension.

Authors:  H G Predel; W Mainka; W Schillings; H Knigge; J Montiel; J Fallois; R Agrawal; T Schramm; C Graf; B M Giannetti; B Bjarnason-Wehrens; U Prinz; R E Rost
Journal:  J Hum Hypertens       Date:  2001-10       Impact factor: 3.012

8.  Exercise tolerance with nebivolol and atenolol.

Authors:  L M Van Bortel; M A van Baak
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

9.  Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.

Authors:  Neil Chapman; Choon Lan Chang; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Journal:  Circulation       Date:  2008-06-16       Impact factor: 29.690

10.  Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people.

Authors:  Eleni Rapsomaniki; Adam Timmis; Julie George; Mar Pujades-Rodriguez; Anoop D Shah; Spiros Denaxas; Ian R White; Mark J Caulfield; John E Deanfield; Liam Smeeth; Bryan Williams; Aroon Hingorani; Harry Hemingway
Journal:  Lancet       Date:  2014-05-31       Impact factor: 79.321

View more
  2 in total

Review 1.  [Management of arterial hypertension].

Authors:  J A Wermelt; H Schunkert
Journal:  Herz       Date:  2017-08       Impact factor: 1.443

2.  Exercise Hypertension in Athletes.

Authors:  Karsten Keller; Katharina Hartung; Luis Del Castillo Carillo; Julia Treiber; Florian Stock; Chantal Schröder; Florian Hugenschmidt; Birgit Friedmann-Bette
Journal:  J Clin Med       Date:  2022-08-19       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.